Integra LifeSciences (NASDAQ:IART) Issues Quarterly Earnings Results

Integra LifeSciences (NASDAQ:IART) posted its quarterly earnings data on Monday. The life sciences company reported $0.55 EPS for the quarter, meeting analysts’ consensus estimates of $0.55, Briefing.com reports. Integra LifeSciences had a net margin of 4.39% and a return on equity of 15.19%. The company had revenue of $368.90 million for the quarter, compared to analyst estimates of $361.96 million. During the same period in the prior year, the firm posted $0.74 EPS. The company’s quarterly revenue was down 3.2% on a year-over-year basis.

Integra LifeSciences Trading Down 19.9 %

NASDAQ:IART opened at $23.14 on Tuesday. Integra LifeSciences has a one year low of $22.36 and a one year high of $51.12. The company has a market cap of $1.82 billion, a PE ratio of 27.88, a PEG ratio of 0.87 and a beta of 1.17. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.45 and a quick ratio of 2.18. The firm has a 50-day moving average of $33.33 and a 200-day moving average of $38.33.

Wall Street Analyst Weigh In

A number of brokerages have commented on IART. Oppenheimer cut shares of Integra LifeSciences from an “outperform” rating to a “market perform” rating in a research report on Tuesday. StockNews.com downgraded Integra LifeSciences from a “buy” rating to a “hold” rating in a report on Tuesday, April 30th. JMP Securities cut their price target on Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating on the stock in a report on Thursday, February 29th. Truist Financial lowered their price objective on shares of Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating for the company in a research note on Friday, March 1st. Finally, Bank of America reduced their price target on shares of Integra LifeSciences from $42.00 to $26.00 and set an “underperform” rating for the company in a report on Tuesday. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, Integra LifeSciences has an average rating of “Hold” and an average target price of $40.60.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.